Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 6.65
NAS:EDIT's Cash-to-Debt is ranked lower than
58% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:EDIT: 6.65 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:EDIT' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.11  Med: 19.68 Max: No Debt
Current: 6.65
Equity-to-Asset 0.50
NAS:EDIT's Equity-to-Asset is ranked lower than
68% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:EDIT: 0.50 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:EDIT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.56  Med: 0.65 Max: 0.81
Current: 0.5
-0.56
0.81
Altman Z-Score: 1.38
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -2072.90
NAS:EDIT's Operating Margin % is ranked lower than
83% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:EDIT: -2072.90 )
Ranked among companies with meaningful Operating Margin % only.
NAS:EDIT' s Operating Margin % Range Over the Past 10 Years
Min: -2167.71  Med: -1886.67 Max: -1605.62
Current: -2072.9
-2167.71
-1605.62
Net Margin % -2091.36
NAS:EDIT's Net Margin % is ranked lower than
83% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NAS:EDIT: -2091.36 )
Ranked among companies with meaningful Net Margin % only.
NAS:EDIT' s Net Margin % Range Over the Past 10 Years
Min: -4475.14  Med: -3040.34 Max: -1605.53
Current: -2091.36
-4475.14
-1605.53
ROE % -66.74
NAS:EDIT's ROE % is ranked lower than
64% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:EDIT: -66.74 )
Ranked among companies with meaningful ROE % only.
NAS:EDIT' s ROE % Range Over the Past 10 Years
Min: -377.64  Med: -377.64 Max: -66.74
Current: -66.74
-377.64
-66.74
ROA % -39.71
NAS:EDIT's ROA % is ranked lower than
58% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAS:EDIT: -39.71 )
Ranked among companies with meaningful ROA % only.
NAS:EDIT' s ROA % Range Over the Past 10 Years
Min: -186.58  Med: -90.25 Max: -39.71
Current: -39.71
-186.58
-39.71
ROC (Joel Greenblatt) % -319.05
NAS:EDIT's ROC (Joel Greenblatt) % is ranked higher than
51% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NAS:EDIT: -319.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:EDIT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2186.08  Med: -2178.41 Max: -319.05
Current: -319.05
-2186.08
-319.05
GuruFocus has detected 1 Warning Sign with Editas Medicine Inc $NAS:EDIT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:EDIT's 30-Y Financials

Financials (Next Earnings Date: 2017-11-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

EDIT Guru Trades in Q3 2016

Jim Simons 128,400 sh (+475.68%)
Andreas Halvorsen 1,709,401 sh (unchged)
» More
Q4 2016

EDIT Guru Trades in Q4 2016

Andreas Halvorsen 1,709,401 sh (unchged)
Jim Simons Sold Out
» More
Q1 2017

EDIT Guru Trades in Q1 2017

Paul Tudor Jones 26,185 sh (New)
John Paulson 50,000 sh (New)
Leon Cooperman 50,000 sh (New)
Andreas Halvorsen 1,709,401 sh (unchged)
» More
Q2 2017

EDIT Guru Trades in Q2 2017

Paul Tudor Jones 31,894 sh (+21.80%)
John Paulson 50,000 sh (unchged)
Andreas Halvorsen 1,709,401 sh (unchged)
Leon Cooperman Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:EDIT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Leon Cooperman 2017-06-30 Sold Out 0.04%$13.66 - $22.32 $ 18.422%0
Leon Cooperman 2017-03-31 New Buy0.04%$17.04 - $27.27 $ 18.42-11%50,000
John Paulson 2017-03-31 New Buy0.01%$17.04 - $27.27 $ 18.42-11%50,000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:TGTX, NAS:INSM, NAS:ENTA, NAS:PTCT, NAS:AKAO, NAS:RVNC, NAS:VNDA, NAS:KERX, NAS:ANIK, NAS:ZIOP, NAS:AKBA, NAS:SPPI, NAS:RETA, NAS:ADRO, NAS:ARNA, NAS:FPRX, NAS:CYTK, NAS:ACRS, NAS:INSY, NAS:EPZM » details
Traded in other countries:8EM.Germany,
Headquarter Location:USA
Editas Medicine Inc is a genome editing company which is engaged in treating patients with genetically defined diseases by correcting disease-causing genes.

Editas Medicine Inc is a US-based genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company operates its business in a single segment of Developing and commercializing genome editing technology.

Ratios

vs
industry
vs
history
PB Ratio 4.08
EDIT's PB Ratio is ranked higher than
56% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. EDIT: 4.08 )
Ranked among companies with meaningful PB Ratio only.
EDIT' s PB Ratio Range Over the Past 10 Years
Min: 2.74  Med: 4.32 Max: 7.35
Current: 4.08
2.74
7.35
PS Ratio 125.03
EDIT's PS Ratio is ranked lower than
85% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. EDIT: 125.03 )
Ranked among companies with meaningful PS Ratio only.
EDIT' s PS Ratio Range Over the Past 10 Years
Min: 57.28  Med: 105.34 Max: 152.64
Current: 125.03
57.28
152.64
Price-to-Free-Cash-Flow 52.08
EDIT's Price-to-Free-Cash-Flow is ranked higher than
58% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. EDIT: 52.08 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
EDIT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 22.64  Med: 30.78 Max: 62.18
Current: 52.08
22.64
62.18
Price-to-Operating-Cash-Flow 44.00
EDIT's Price-to-Operating-Cash-Flow is ranked higher than
58% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. EDIT: 44.00 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
EDIT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 20.08  Med: 26.59 Max: 52.51
Current: 44
20.08
52.51
EV-to-EBIT -4.19
EDIT's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. EDIT: -4.19 )
Ranked among companies with meaningful EV-to-EBIT only.
EDIT' s EV-to-EBIT Range Over the Past 10 Years
Min: -17.5  Med: -5.3 Max: -2.4
Current: -4.19
-17.5
-2.4
EV-to-EBITDA -4.27
EDIT's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. EDIT: -4.27 )
Ranked among companies with meaningful EV-to-EBITDA only.
EDIT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.7  Med: -5.4 Max: -2.5
Current: -4.27
-17.7
-2.5
Current Ratio 6.73
EDIT's Current Ratio is ranked higher than
69% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. EDIT: 6.73 )
Ranked among companies with meaningful Current Ratio only.
EDIT' s Current Ratio Range Over the Past 10 Years
Min: 1.74  Med: 14.79 Max: 28.66
Current: 6.73
1.74
28.66
Quick Ratio 6.73
EDIT's Quick Ratio is ranked higher than
70% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. EDIT: 6.73 )
Ranked among companies with meaningful Quick Ratio only.
EDIT' s Quick Ratio Range Over the Past 10 Years
Min: 1.74  Med: 14.79 Max: 28.66
Current: 6.73
1.74
28.66
Days Sales Outstanding 53.08
EDIT's Days Sales Outstanding is ranked higher than
55% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. EDIT: 53.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
EDIT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.31  Med: 116.82 Max: 228.32
Current: 53.08
5.31
228.32

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 5.33
EDIT's Price-to-Net-Cash is ranked higher than
71% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. EDIT: 5.33 )
Ranked among companies with meaningful Price-to-Net-Cash only.
EDIT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.75  Med: 5.57 Max: 6.96
Current: 5.33
3.75
6.96
Price-to-Net-Current-Asset-Value 5.22
EDIT's Price-to-Net-Current-Asset-Value is ranked higher than
69% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. EDIT: 5.22 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
EDIT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.65  Med: 5.47 Max: 6.84
Current: 5.22
3.65
6.84
Price-to-Tangible-Book 4.07
EDIT's Price-to-Tangible-Book is ranked higher than
65% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. EDIT: 4.07 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
EDIT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.82  Med: 4.36 Max: 6.28
Current: 4.07
2.82
6.28
Price-to-Median-PS-Value 1.19
EDIT's Price-to-Median-PS-Value is ranked lower than
56% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. EDIT: 1.19 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
EDIT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.71  Med: 0.98 Max: 1.27
Current: 1.19
0.71
1.27
Earnings Yield (Greenblatt) % -23.90
EDIT's Earnings Yield (Greenblatt) % is ranked lower than
79% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. EDIT: -23.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
EDIT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -41.1  Med: -18.9 Max: -5.7
Current: -23.9
-41.1
-5.7

More Statistics

Revenue (TTM) (Mil) $5.64
EPS (TTM) $ -3.25
Short Percentage of Float26.24%
52-Week Range $12.43 - 29.20
Shares Outstanding (Mil)41.63

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 10 16 58
EPS ($) -3.57 -4.38 -4.93
EPS without NRI ($) -3.57 -4.38 -4.93
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:EDIT

Headlines

Articles On GuruFocus.com
Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towa Aug 09 2017 
Editas Medicine Announces Second Quarter 2017 Results and Update Aug 09 2017 
Editas Medicine to Host Conference Call Discussing Second Quarter 2017 Corporate Update and Results Aug 07 2017 
Editas Medicine to Participate in Investor Conferences in June Jun 13 2017 
Editas Medicine Names Andrew Hirsch to Board of Directors May 31 2017 
Editas Medicine Announces First Quarter 2017 Results and Update May 15 2017 
Editas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas May 13 2017 
Editas Medicine Announces Pre-Clinical Data for Program to Treat Sickle Cell Disease and Beta-Thalas May 11 2017 
Editas Medicine to Host Conference Call Discussing First Quarter 2017 Corporate Update and Results May 08 2017 
Editas Medicine to Present at Investor Conferences in May May 08 2017 

More From Other Websites
This Stock Could Be the Tesla of Healthcare Aug 20 2017
Edited Transcript of EDIT earnings conference call or presentation 9-Aug-17 9:00pm GMT Aug 14 2017
Editas Medicine (EDIT) Looks Good: Stock Moves Up 11.3% Aug 14 2017
[$$] Gormley's Take: Biotech Companies Are Steering Clear of Gene Editing's Ethical Concerns Aug 14 2017
Editas reports 2Q loss Aug 09 2017
Editas Medicine Announces Second Quarter 2017 Results and Update Aug 09 2017
Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress... Aug 09 2017
Here's Why Editas Medicine Rose as Much as 15.9% Monday Aug 08 2017
Editas Medicine to Host Conference Call Discussing Second Quarter 2017 Corporate Update and Results Aug 07 2017
Editas Medicine, Inc. breached its 50 day moving average in a Bullish Manner : EDIT-US : July 31,... Jul 31 2017
ETFs with exposure to Editas Medicine, Inc. : July 24, 2017 Jul 24 2017
Should You Buy Into the Hype Surrounding These Stocks? Jul 18 2017
Today's Research Reports on Stocks to Watch: Editas Medicine and Cymabay Therapeutics Jul 18 2017
Never Will I Ever Buy Preclinical Biotech Stocks. No Way! Jul 15 2017
Here's Why Editas Medicine Inc. Bounced Up 20% in June Jul 11 2017
Editas Medicine, Inc. breached its 50 day moving average in a Bearish Manner : EDIT-US : July 11,... Jul 11 2017
Editas Medicine, Inc. – Value Analysis (NASDAQ:EDIT) : July 3, 2017 Jul 03 2017
Editas Medicine, Inc. breached its 50 day moving average in a Bearish Manner : EDIT-US : June 30,... Jun 30 2017
Editas Medicine to Participate in Investor Conferences in June Jun 13 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}